Scottsdale 1/18/2014 4:00:00 AM
QualityStocks News - Puma Biotechnology (PBYI) Neratinib Development Continues, Compelling HER2-Focused Treatment for Breast and Other Cancers
QualityStocks would like to highlight Puma Biotechnology, Inc. (NYSE: PBYI), focused on in-licensing innovative drug candidates that are undergoing or have already completed initial clinical testing for the treatment of various forms of cancer, and then seeking to further develop these drug candidates for commercial use. Initial work is on developing Neratinib for patients with HER2-positive metastic breast cancer.
In the company’s news,
Puma Biotechnology recently garnered considerable attention for their initial foray, PB272 (oral Neratinib), both as a single agent and in combination with other drugs or chemotherapeutic agents for treating a variety of cancers.
The company held a conference call last month (Dec 17) to go over the ongoing Phase 2 and 3 clinical trial progress achieved in PB272, which is an extremely potent irreversible tyrosine kinase inhibitor focusing on the HER2 (human epidermal growth factor receptor 2) mutation, whose over-expression is typical among breast and other aggressive cancers, and which is strongly associated with both an increased recurrence rate of disease and poor prognosis. HER2 (or ERBB2, the gene in which the receptor tyrosine-protein kinase erbB-2 is encoded) has become an accepted biomarker standard for roughly 30% of breast cancer patients but the typical indication, approved drug Trastuzumab (Herceptin), is useful only in cases of HER2-positive individuals exhibiting over-expression and poses serious cardiotoxicity risks, not to mention the high cost of the drug. It is noteworthy here to point out that Journal of Clinical Oncology-published data from back in March of 2010, shows Phase 2 clinical trial work comparing Neratinib (as a single agent) and Trastuzumab in HER2+ metastatic breast cancer patients, clearly indicating that Neratinib was well tolerated, even by patients who had previously undergone Trastuzumab treatment.
Significant progress in HER2 mutated non-small cell lung cancer with PB272, as well as HER2-negative breast cancer patients with the HER2 mutation, adds significant weight to the report earlier last month (Dec 4) of top line results from the Phase 2 neoadjuvant treatment work done in breast cancer (I-SPY 2 TRIAL). I-SPY 2 essentially looked at Stage 2 (HER2-positive breast cancer) and higher women, to see how effective Neratinib could be in combination with standard chemotherapy in a neoadjuvant context and having graduated this unique trial, which is a collaborative effort from 20 major cancer research centers across the U.S. (as well as the FDA and major industry and foundation supporters), with statistically superior performance (Paclitaxel plus Neratinib versus Paclitaxel plus Trastuzuma), PBYI has been really starting to turn heads in the oncology space for their technology.
The recent conference call also gave PBYI a chance to look at their clinical trial progress in solid tumors that have an HER2 activating mutation (basket trial) and the broad-spectrum applicability evident in this open-label work further reinforces just how compelling their HER2 mutation-focused technology really is. The PBYI technology approach is more like Galena Biopharma’s (GALE) NeuVax technology, which uses the HER2-derived E75 peptide and immune adjuvant granulocyte macrophage colony stimulating factor to induce a targeted “killer” T cell assault on over-expressing cells, going right after root phenomena. In the case of PBYI, they are going straight after signal transduction through the epidermal growth factor receptors (EGFRs, for HER1 and HER4 as well). Efficacy in combination and as a standalone agent is abundantly clear from the clinical trial work and investors should take note of the potential for broad-spectrum Neratinib applicability in the oncology space as a driving factor for future performance of the stock.
2014 is shaping up to be a momentous year for PBYI, with Phase 2 or 3 trials across the board for their evolving pipeline. Investors should keep a close eye on the company for announcement of further results on Neratinib, with the Temsirolimus plus Neratinib trial in metastatic HER2-amplified (triple negative) breast cancer and the Neratinib plus Capecitabine vs Lapatinib plus Capecitabine trial in HER2+ metastatic breast cancer, likely occupying center stage.
About QualityStocks
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit www.QualityStocks.net
To connect with QualityStocks via Facebook, please visit http://Facebook.com/QualityStocksPage
To connect with QualityStocks via Twitter, please visit http://Twitter.com/QualityStocks
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
